51022-69-6
Chemical Structure
Amcinonide
Synonym(s): CL-34699
- CAS No.: 51022-69-6
- Formula:C28H35FO7
- Molecular Weight:502.57
IUPAC Name: 2-((6a'S,6b'R,7'S,8a'S,8b'S,11a'R,12a'S,12b'S)-6b'-fluoro-7'-hydroxy-6a',8a'-dimethyl-4'-oxo-1',2',4',6a',6b',7',8',8a',11a',12',12a',12b'-dodecahydro-8b'H-spiro[cyclopentane-1,10'-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxole]-8b'-yl)-2-oxoethyl acetate
InChIKey: ILKJAFIWWBXGDU-MOGDOJJUSA-N
SMILES: C[C@@]12[C@@]3(C(COC(C)=O)=O)[C@@](OC4(O3)CCCC4)([H])C[C@@]1([H])[C@]5([H])CCC6=CC(C=C[C@]6(C)[C@@]5(F)[C@@H](O)C2)=O
Biological Activity: Amcinonide is an inhibitor of NO release (IC50 = 3.38 nM). Amcinonide inhibits NNC-induced expression of the proinflammatory genes iNOS, TNF-α, and IL-1β in glial cells. Amcinonide reduces the numbers of T6+/Ia+ cells with a concomitant increase in T6+/Ia- cells. Amcinonide induces a selective reduction in expression of Ia antigens. Amcinonide can also be studied in research for eczematous dermatitis[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Amcinonide | 99.11% | Amcinonide is an inhibitor of NO release (IC50 = 3.38 nM). Amcinonide inhibits NNC-induced expression of the proinflammatory genes iNOS, TNF-α, and IL-1β in glial cells. Amcinonide reduces the numbers of T6+/Ia+ cells with a concomitant increase in T6+/Ia- cells. Amcinonide induces a selective reduction in expression of Ia antigens. Amcinonide can also be studied in research for eczematous dermatitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Amcinonide (Standard) | ≥98% | Amcinonide (Standard) is the analytical standard of Amcinonide. This product is intended for research and analytical applications. Amcinonide is an inhibitor of NO release (IC50 = 3.38 nM). Amcinonide inhibits NNC-induced expression of the proinflammatory genes iNOS, TNF-α, and IL-1β in glial cells. Amcinonide reduces the numbers of T6+/Ia+ cells with a concomitant increase in T6+/Ia- cells. Amcinonide induces a selective reduction in expression of Ia antigens. Amcinonide can also be studied in research for eczematous dermatitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Hong J, et al. Identification and characterization of triamcinolone acetonide, a microglial-activation inhibitor. Immunopharmacol Immunotoxicol. 2012 Dec;34(6):912-918. [Content Brief]
- [2]. Berman B, et al. Modulation of expression of epidermal Langerhans cell properties following in situ exposure to glucocorticosteroids. J Invest Dermatol. 1983 Mar;80(3):168-171. [Content Brief]
- [3]. Bickers D. R. (1984). A comparative study of amcinonide and halcinonide in the treatment of eczematous dermatitis. Cutis, 34(2), 190–194. [Content Brief]
